Trial intelligence / Profile preview

HIFU combined with PD-1 inhibitor and fruquintinib for MSS colorectal cancer with liver metastases

ChiCTR2400082391Phase 2Recruiting

Sponsor
Suining Central Hospital
Start
Mar 2024
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Suining Central Hospital. Primary endpoint: Objective response rate. Started Mar 2024; status: recruiting.

02

Drugs

fruquintinib
03

Conditions

colorectal cancer (CRC)

Beyond the preview

Go deeper on ChiCTR2400082391.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2400082391.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call